Achieving hypoxia-inducible gene expression in tumors

Cancer Biology and Therapy

Volumn 4, Issue 4, 2005, Pages 359-364

  Marignol, L ^a   Lawler, M ^a   Coffey, Mary ^b   Hollywood, D ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Gene therapy; Hypoxia; Hypoxia response element

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; BACTERIAL ENZYME; CYTOCHROME P450 REDUCTASE; CYTOSINE DEAMINASE; ERYTHROPOIETIN; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HERPESVIRUS VECTOR; HYPOXIA INDUCIBLE FACTOR 1; NITROREDUCTASE; OXYGEN; PHOSPHOGLYCERATE KINASE; PRODRUG; RECOMBINANT ENZYME; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN;

APOPTOSIS; CELL HYPOXIA; DNA RESPONSIVE ELEMENT; DRUG SENSITIVITY; ENZYME THERAPY; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; HUMAN; HYPOXIA; METASTASIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXYGEN CONCENTRATION; OXYGEN TENSION; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REPORTER GENE; REVIEW; SOLID TUMOR; SUICIDE GENE THERAPY; TATA BOX; TRANSCRIPTION REGULATION; TREATMENT FAILURE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL HYPOXIA; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RESPONSE ELEMENTS;

EID: 25144436926     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9:539-49.
2. Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979; 52:650-6.
3. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88-91.
4. Patterson AV, Saunders MP, Greco O. Prodrugs in genetic chemoradiotherapy. Curr Pharm Des 2003; 9:2131-54.
5. Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol 2003; 1:48-70.
6. Foley R, Lawler M, Hollywood D. Gene-based therapy in prostate cancer. Lancet Oncol 2004; 5:469-79.
7. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003; 22:3213-20.
8. Blancher C, Harris AL. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target. Cancer Metastasis Rev 1998; 17:187-94.
9. O'Rourke JF, Dachs GU, Gleadle JM, Maxwell PH, Pugh CW, Stratford IJ, Wood SM, Ratcliffe PJ. Hypoxia response elements. Oncol Res 1997; 9:327-32.
10. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994; 269:4355-9.
11. Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 1995; 270:29083-9.
12. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 1994; 91:6496-500.
13. Semenza GL. Transcriptional regulation of gene expression: Mechanisms and pathophysiology. Hum Mutat 1994; 3:180-99.
14. Lu S, Gu X, Hoestje S, Epner DE. Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter. Biochim Biophys Acta 2002; 1574:152-6.
15. Goldberg MA, Gaut CC, Bunn HF. Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood 1991; 77:271-7.
16. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12:5447-54.
17. Galson DL, Tsuchiya T, Tendler DS, Huang LE, Ren Y, Ogura T, Bunn HF. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. Mol Cell Biol 1995; 15:2135-44.
18. Shibata T, Akiyama N, Noda M, Sasai K, Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 1998; 42:913-6.
19. Ruan H, Wang J, Hu L, Lin CS, Lamborn KR, Deen DF. Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX. Neoplasia 1999; 1:431-7.
20. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 1994; 91:6496-500.
21. Binley K, Iqball S, Kingsman A, Kingsman S, Naylor S. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 1999; 6:1721-7.
22. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, Harris AL. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3:515-20.
23. Gleadle JM, Ebert BL, Firth JD, Ratcliffe PJ. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol 1995; 268:C1362-8.
24. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16:4604-13.
25. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 2000; 7:493-8.
26. Shibata T, Akiyama N, Noda M, Sasai K, Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 1998; 42:913-6.
27. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002; 4:40-8.
28. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271:32529-37.
29. Graven KK, Yu Q, Pan D, Roncarati JS, Farber HW. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim Biophys Acta 1999; 1447:208-18.
30. Ruan H, Su H, Hu L, Lamborn KR, Kan YW, Deen DF. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 2001; 3:255-63.
31. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994; 29:427-31.
32. Terris DJ, Dunphy EP. Oxygen tension measurements of head and neck cancers. Arch Otolaryngol Head Neck Surg 1994; 120:283-7.
33. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 2000; 60:2936-41.
34. Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, Airley R, Honess D, van der Kogel AJ, Wolf CR, Stratford IJ. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther 2002; 9:946-54.
35. Ruan H, Hu L, Wang J, Ozawa T. Hypoxia-inducible expression of BAX: Application in tumour-targeted gene therapy Neurosurg. Focus 2000; 8(4).
36. Hernandez-Alcoceba R, Pihalja M, Nunez G, Clarke MF. Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther 2001; 8:298-307.